期刊文献+

免疫磁性海藻酸钠载药纳米微球的制备与评价 被引量:8

Preparation and evaluation of immunomagnetic alginate sodium drug loaded microspheres
暂未订购
导出
摘要 靶向治疗系统是目前研究的热点,用微乳化-离子交联方法制备包覆阿霉素的碳包铁/海藻酸钠复合纳米微球,以水溶性碳二亚胺为交联剂,将载药微球与单抗Hab18连接,制备出了免疫磁性药物纳米微球。对该免疫磁性微球的理化性能进行了表征,同时检测了免疫磁性微球中抗体的活性和免疫磁性微球与靶细胞的体外结合情况,结果表明,免疫磁性药物纳米微球平均粒径约为171.2nm,外观为球型,铁含量为14.6%,载药量为10.8%,且具有强磁响应性和长时间药物缓释效果。同时在体外该微球能够与靶细胞特异性结合。这种免疫磁性药物纳米微球有望成为一种优良的靶向肿瘤药物载体。 Immunomagnetic drug loaded microspheres (IMDM) were prepared by cross-linking the monoclonal antibody Habl8 to alginate magnetic doxorubicin microspheres. The morphology of IMDM was characterized by transmission electron microscopy. The size distribution of IMDM was determined by laser light scattering. The amount of Fe and drug containing in the microspheres were examined respectively. Flow cytomctry was used to evaluate the immunological activity of antibody on IMDM, ELISA method was used to evaluate the specific combination between IMDM and human liver tumor SMMC-7721 cells. The results showed that IMDM had spherical morphology, the average size was approximately 171.2 ± 2.21nm. The Fe content in the IMDM was 14.6%, and the drug loading was 10.8%. IMDM had a good response to the magnetic field and had long time drug releasing property. The immunological activity of antibody conjugated with IMDM was well remained ; IMDM could also combine with SMMC- 7721 cells, IMDM with magnetic and specific targeting ruction could be a promising carriers for cancer therapy.
出处 《中国生物医学工程学报》 CAS CSCD 北大核心 2006年第3期305-309,共5页 Chinese Journal of Biomedical Engineering
基金 广东省自然科学基金重点项目(No.04006966) 广东省卫生科研基金(No.A2003697)。
关键词 磁性微球 海藻酸钠 阿霉素 Hab18单抗 magnetic microspheres alginate doxorubicin Habl 8 antibody
  • 相关文献

参考文献9

二级参考文献19

  • 1陈志南,刘彦仿.抗人肝细胞癌单克隆抗体及其F(ab‘)片段对荷人肝癌...?[J].中华医学杂志,1989,69(10):566-568. 被引量:8
  • 2布卡,盛洁,谢蜀生,魏树礼.抗人膀胱癌免疫毫微球的制备及活性检测[J].中华微生物学和免疫学杂志,1996,16(1):54-57. 被引量:21
  • 3刘秀洞.膜乳化法制备壳聚糖/海藻酸微胶囊.第九届全国生物化工学术会议论文集[M].-,2000.475-477.
  • 4Syrigos KN ,Rowlinson Busza G,Epenetos AA. In vitro cytotoxicity following specific activation of amygadalin by beta-glucosidase conjugated to a bladder cancer-associated monoclonal antibody [ J ].Int J Cancer, 1998, 78(6): 712-719.
  • 5Monks NR, Blakey DC, East S J, et al. DNA interstrand crosslinking and TP53 status as determinants of tumour cellsensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767 [ J].Eur J Cancer, 2002, 38(11): 1543-1552.
  • 6Francis RJ, Sharma SK, Springer C, et al. A phase Ⅰ trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours [J]. BrJ Cancer, 2002, 87(6): 600-607.
  • 7Searle F, Bier C, Buckley RG, et al. The potential of carboxypeptidase G2-antibody conjugates as anti-tumor agents. Ⅰ Preparation of antihuman chorionic gonadotrophin- carboxypeptidase G2 and cytotoxity of the conjugate against JAR choriocarcinoma cells
  • 8Jung M. Antibody directed enzyme prodrug therapy (ADEPT) and related approaches for anticancer therapy [ J ]. Mini Rev Med Chem, 2001, 1(4): 399-407.
  • 9Tietze LF, Herzig T, Fecher A, et al. Highly selective glycosylated prodrugs of cytostatic CC-1065 analogues for antibody-directed enzyme tumor therapy[ J]. Chembiochem, 2001, 2 (10): 758-765.
  • 10Kwon HY, Hong SP, Hahn DH, et al. Apoptosis induction of Persicae Semen extract in human promyelocytic leukemia ( HL-60 )cells[J]. Arch Pharm Res, 2003, 26(2): 157-161.

共引文献51

同被引文献138

引证文献8

二级引证文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部